Avadel Pharmaceuticals plc Ordinary Share (AVDL) is a publicly traded Healthcare sector company. As of May 21, 2026, AVDL trades at $21.39 with a market cap of $2.12B and a P/E ratio of -10.70. AVDL moved +0.00% today. Year to date, AVDL is +41.07%; over the trailing twelve months it is +140.44%. Its 52-week range spans $6.38 to $23.57. Analyst consensus is buy with an average price target of $21.25. Rallies surfaces AVDL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
AVDL financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. AVDL recently traded at $21.39. Market cap is $2.12B. P/E ratio is -10.70. Revenue is $27.96M.
| Metric | Value |
|---|---|
| Price | $21.39 |
| Market Cap | $2.12B |
| P/E Ratio | -10.70 |
| EPS | $-2.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $23.57 |
| 52-Week Low | $6.38 |
| Volume | 200 |
| Avg Volume | 0 |
| Revenue (TTM) | $27.96M |
| Net Income | $-160.28M |
| Gross Margin | 96.97% |
| Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2023 | $27.96M | $-160.28M | $-2.00 |
| 2022 | $0 | $-137.46M | $-2.29 |
| 2021 | $0 | $-77.33M | $-1.32 |
| 2020 | $22.33M | $7.03M | $0.13 |
14 analysts cover AVDL: 0 strong buy, 8 buy, 6 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $21.25.